Please assess the completion status of the following clinical trial:

Trial Title: R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* One of the following Biopsy-confirmed, aggressive non-Hodgkin's lymphoma~  1. Diffuse large B-cell lymphoma~ 2. Mediastinal (thymic) B-cell lymphoma~* Any stage (I through IV) as defined by the Ann Arbor staging system~* ECOG performance status of 0 to 2~* Radiographically measurable disease~* No more than 3 cycles of chemotherapy for lymphoma~* Greater than or equal to 18 years~* Adequate pulmonary, cardiac, hepatic, or renal function~* HIV antibody negative~* Women- Not pregnant or breastfeeding~* Men of reproductive potential must agree to use contraception~Exclusion Criteria:~* Patients with the following aggressive lymphomas are not eligible:~  1. Mantle cell~ 2. Lymphoblastic~ 3. Burkitt's~ 4. Mycosis fungoides/Sezary's syndrome~ 5. HTLV-1 associated T-cell leukemia/lymphoma~ 6. Primary CNS lymphoma~ 7. HIV-associated lymphoma~ 8. Transformed lymphomas~ 9. Immunodeficiency-associated lymphomas~* Previous diagnosis of another hematologic malignancies~* Progressive disease on CHOP or Rituximab-CHOP~* Active CNS involvement by lymphoma~* Serious co-morbid disease that could preclude full participation in study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET Negative (Type: ACTIVE_COMPARATOR): R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a negative PET scan will complete their chemotherapy regimen as prescribed by their oncologist.
- PET Positive (Type: ACTIVE_COMPARATOR): R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a positive PET scan will receive two cycles of R-ICE (rituximab, ifosfamide, carboplatin, etoposide) followed by HiCy (high-dose cyclophosphamide).

Based on this trial design, predict the completion outcome and termination type (if applicable).